"Currently, people with a prescription can buy the most popular drugs, Wegovy and Zepbound, directly from Novo Nordisk and Eli Lilly, respectively, for $499 each. Under the new deal, Wegovy will be available for $350, as will Ozempic. And Zepbound will be available at "an average" of $346. While the prices are lower, the out-of-pocket costs are still likely to be more than most people would pay if they went through an insurance plan,"
"But even with the lower prices for some, Americans are still paying more than foreign counterparts. As Senator Bernie Sanders (I-Vt.) noted last year, while Novo Nordisk set Ozempic's list price at nearly $1,000 in the US and the new deal is as low as $245, the drug costs just $155 in Canada, $122 in Italy, $71 in France, and $59 in Germany."
The administration announced new direct-to-consumer prices for GLP-1 drugs, reducing some list prices from $499 to about $350 and averaging $346 for Zepbound. Out-of-pocket payments made outside insurance are likely higher than insured costs and will not count toward out-of-pocket maximums. Experts generally expect direct-to-consumer sales will not significantly lower overall drug costs. The deal's effect on commercial insurance pricing remains unclear. U.S. prices for GLP-1 drugs remain substantially higher than prices in Canada, Europe, and Japan. A JAMA Network Open study estimated manufacturing costs for this drug class under $5 per month.
Read at Ars Technica
Unable to calculate read time
Collection
[
|
...
]